DRAGON PHARMACEUTICAL INC Form 15-12G July 22, 2010

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 000-27937

DRAGON PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter)

650 West Georgia Street, Suite 310 Vancouver, British Columbia Canada V6B 4N9 (604) 669-8817 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

> Common Stock, \$.001 par value (Title of each class of securities covered by this form)

None (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

R u 1 e[X] 12g-4(a)(1)u R 1 e[ ] 12g-4(a)(2)R u 1 e[X]12h-3(b)(1)(i)u 1 e[] R 12h-3(b)(1)(ii) Rule 15d-6 []

Approximate number of holders of record as of the certification or notice date: 2

## Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 15-12G

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Dragon Pharmaceutical Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

DATE: July 22, 2010

By: /s/ Yanlin Han Name: Yanlin Han Title: Chief Executive Officer